A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacodynamics of SYNB1020 in Hepatic Insufficiency and Cirrhosis Patients

Trial Profile

A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacodynamics of SYNB1020 in Hepatic Insufficiency and Cirrhosis Patients

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Apr 2018

At a glance

  • Drugs SYNB 1020 (Primary)
  • Indications Hyperammonaemia; Liver cirrhosis
  • Focus Adverse reactions
  • Sponsors Synlogic
  • Most Recent Events

    • 20 Mar 2018 According to a Synlogic media release, Company expects to present top-line data from this trial by year end 2018.
    • 26 Feb 2018 Status changed from planning to recruiting.
    • 05 Jan 2018 According to a Synlogic media release, an IND application has been cleared by the US FDA to initiate this trial. This trial is expected to be initiated in the first quarter of 2018, with interim data expected by year-end.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top